SCHEDULE: Celadon Partners Boosts Senti Bio Stake to 54.6%

Celadon Partners has increased its stake in Senti Biosciences to 54.6% through a significant investment in convertible notes, signaling a strategic shift for the gene therapy company.

Summary

• Celadon Partners, through its affiliated entities Celadon Partners SPV 24, Celadon Partners, LLC, and CPIF II-7 Limited, has amended its Schedule 13D filing to reflect an increased beneficial ownership of Senti Biosciences, Inc. common stock.
• The reporting persons now beneficially own 25,748,890 shares, representing 54.6% of the outstanding common stock.
• This ownership includes an assumed issuance of 15,971,890 shares of common stock upon the exchange of Initial Notes purchased under a Securities Purchase Agreement dated April 27, 2026.
• The total investment involves an initial tranche of $10.0 million in aggregate principal amount of Notes, with a potential second tranche of up to $30.0 million in Additional Notes.
• The Notes are senior, secured indebtedness of Senti Holdings, Inc., guaranteed by its ultimate parent company.
• Holders of the Notes may convert them into shares of Senti Holdings common stock at an initial conversion price of $0.6261 per share, subject to adjustments.
• The Issuer also has the right to convert remaining outstanding Notes under certain conditions, including majority holder consent or consummation of a CVR Transaction.
• The net proceeds from the sale of the Notes are intended for general corporate purposes and to advance CMC and clinical trials for Senti Biosciences' product candidate, SENTI-202.
• The reporting persons also intend to discuss potential restructuring or M&A transactions with the Issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development due to the substantial capital infusion and strategic investment, which is crucial for advancing the company's product candidate. However, the significant ownership concentration and reliance on future milestones introduce some caution.

Positives

• Significant capital infusion of $10.0 million initially, with potential for up to $30.0 million more, providing crucial funding for Senti Biosciences' operations and product development.
• The investment is earmarked for advancing the company's product candidate, SENTI-202, which could lead to future revenue streams and market success.
• Celadon Partners' increased stake and potential involvement in strategic discussions suggest a strong commitment and belief in Senti Biosciences' long-term prospects.
• The convertible note structure allows for flexibility, potentially converting into equity and strengthening the company's balance sheet.

Negatives

• The significant ownership by a single entity (Celadon Partners) could lead to concentrated control and potentially limit strategic options for the company.
• The conversion price of $0.6261 per share for the Notes may indicate a valuation expectation that could be a benchmark for future equity issuances.
• The transaction is subject to closing conditions, including stockholder approval and a holding company reorganization, which introduce execution risk.

Risks

• The success of SENTI-202 is subject to regulatory and sales milestones, as indicated by the potential CVR Transaction payout.
• The company's ability to secure the full $30.0 million in Additional Notes is contingent on Celadon's discretion and the satisfaction of closing conditions.
• The Holding Company Reorganization and the potential CVR Transaction introduce complexities and potential delays.
• The Notes are subject to negative pledges and covenants, which may restrict the Issuer's future financial flexibility.

Future Outlook

The company intends to use substantially all net proceeds from the Notes for general corporate purposes and to advance CMC and clinical trials for its product candidate, SENTI-202. Discussions regarding potential restructuring or M&A transactions are also planned.

Industry Context

StockSavvy.ai notes that this significant investment and increased stake by Celadon Partners in Senti Biosciences, a gene therapy company, highlights continued investor interest in the biotech sector, particularly in companies with promising drug candidates like SENTI-202. The capital infusion is critical for advancing clinical trials, a common need for companies in this stage of development.

Related Party Transactions

• The Securities Purchase Agreement involves CPIF II-7 Limited, an entity affiliated with Celadon Partners, purchasing Notes from Senti Biosciences' subsidiaries.
• A potential CVR Transaction involves an entity affiliated with Celadon merging with Senti Holdings, which would be a related party transaction.

Stakeholder Impact

• Shareholders: The transaction involves potential dilution through the conversion of Notes into shares. The CVR Transaction offers potential upside based on product success. Existing shareholders will see a significant increase in Celadon Partners' ownership.
• Creditors: The Notes represent senior, secured indebtedness of Senti Holdings, Inc., guaranteed by its parent, which could impact the company's leverage and debt servicing obligations.
• Employees: Continued funding for clinical trials and operations may provide job security and opportunities for growth within the company.

Next Steps

• Completion of the Holding Company Reorganization.
• Satisfaction of closing conditions for the Initial Notes issuance.
• Potential execution of definitive documents for the CVR Transaction within thirty days of the Initial Notes closing.
• Advancement of CMC and clinical trials for SENTI-202 using net proceeds.
• Preliminary discussions with the Issuer regarding restructuring or M&A transactions.

Key Dates

Recommendation

The filing indicates a significant capital infusion and increased strategic interest from Celadon Partners, which is positive for Senti Biosciences' development pipeline. However, the reliance on future milestones for the CVR, the potential for dilution from note conversion, and the complexities of the ongoing reorganization warrant a 'hold' recommendation until further clarity on clinical trial progress and transaction outcomes emerges.

Keywords

Senti Biosciences, Celadon Partners, Schedule 13D, Convertible Notes, Securities Purchase Agreement, SENTI-202, Gene Therapy, Biotechnology, Investment, Capital Raise, Corporate Reorganization